cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Cassava Sciences Inc
43 own
23 watching
Current Price
$11.72
$-0.33
(-2.74%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
960.73M
52-Week High
52-Week High
32.10000
52-Week Low
52-Week Low
8.79000
Average Volume
Average Volume
1.55M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization960.73M
icon52-Week High32.10000
icon52-Week Low8.79000
iconAverage Volume1.55M
iconDividend Yield--
iconP/E Ratio--
What does the Cassava Sciences Inc do?
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer s disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
Read More
How much money does Cassava Sciences Inc make?
News & Events about Cassava Sciences Inc.
Globe Newswire
1 year ago
CHART 1 Decline in Cognition Scores, FAS CHART 2 Decline in Cognition Scores, patients with mild Alzheimer's Figure 1 Historical declines on ADAS-Cog over 18 months in Alzheimer's disease (MMSE 20-30), placebo arms vs simufilam treatment. Simufilam Slowed Cognitive Decline by 38% Versus ...
Globe Newswire
1 year ago
Overactive mTOR Plays a Key Role in Aging and Alzheimers Disease.Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect.Research is Published in Frontiers in Aging, a Peer-reviewed Journal. AUSTIN, Texas, June 27, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a ...
Globe Newswire
1 year ago
Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research, a Peer-Reviewed Journal. AUSTIN, Texas, June 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology ...
Globe Newswire
1 year ago
Over 1,244 Alzheimers patients now enrolled in Phase 3 studies of simufilam.Completion of patient enrollment for Phase 3 program still expected Q4 2023.$187.5 Million Cash and Cash Equivalents at March 31, 2023. AUSTIN, Texas, May 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a...
Globe Newswire
1 year ago
AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwright BioConnect ...
Frequently Asked Questions
Frequently Asked Questions
What is Cassava Sciences Inc share price today?
plus_minus_icon
Can Indians buy Cassava Sciences Inc shares?
plus_minus_icon
How can I buy Cassava Sciences Inc shares from India?
plus_minus_icon
Can Fractional shares of Cassava Sciences Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Cassava Sciences Inc stocks?
plus_minus_icon
What is today’s traded volume of Cassava Sciences Inc?
plus_minus_icon
What is today’s market capitalisation of Cassava Sciences Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Cassava Sciences Inc?
plus_minus_icon
What percentage is Cassava Sciences Inc down from its 52-Week High?
plus_minus_icon
What percentage is Cassava Sciences Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$11.72
$-0.33
(-2.74%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00